Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
- DELIVER Registrational Expansion Cohort is fully enrolled; data from this cohort planned for late 2025 -
- Potential for Biologics License Application submission for U.S. accelerated approval in early 2026 -
WALTHAM, Mass., March 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected registrational dose of 20 mg/kg Q4W (approximate PMO dose). The DELIVER trial is evaluating DYNE-251 in individuals with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping, and updated results from the trial are being presented this week at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
'With Dyne-251, we have the opportunity to deliver a durable and redosable therapy demonstrating clinically meaningful and sustained functional improvement in DMD. The consistency of these new data across multiple endpoints and timepoints underscores the potential of DYNE-251 to meaningfully address the significant unmet need in Duchenne despite available therapies,' said John Cox, president and chief executive officer of Dyne. 'We are rapidly advancing DYNE-251 toward a readout later this year with the potential to submit for U.S. accelerated approval in early 2026 based on a well-established regulatory pathway leveraging dystrophin expression as a surrogate endpoint. If approved, we believe there is an opportunity for rapid adoption by physicians and currently treated patients, as well as those naïve to therapy.'
'I am very encouraged by these new, long-term data for DYNE-251 in the exon 51 skip amenable population and the promise of sustained functional improvement which has continued to elude the DMD community,' said Pat Furlong, founder and president of Parent Project Muscular Dystrophy. 'The investment and innovation in DMD are delivering, and this is a prime example of how the accelerated approval pathway may swiftly enable a new generation of therapies that address unmet and urgent medical needs.'
"The amount of expression of near-full length dystrophin induced by DYNE-251 has not been previously seen with exon 51 skipping agents and is associated with evidence for clinical efficacy,' said Kevin Flanigan M.D., Director, Center for Gene Therapy, Abigail Wexner Research Institute at Nationwide Children's Hospital. 'I look forward to the opportunity to present new functional data and updated safety data at the 2025 MDA Clinical & Scientific Conference.'
This updated assessment of the DELIVER trial evaluating DYNE-251 includes new functional data out to 12 months from 6 patients enrolled in the 20 mg/kg Q4W cohort, and 18-month functional data from 6 patients in the 10 mg/kg Q4W cohort (these participants began transitioning to the 20 mg/kg Q4W regimen after month 6). In addition, updated safety data as of February 7, 2025, continue to demonstrate a favorable safety profile for DYNE-251.
Key findings from the DELIVER Phase 1/2 trial presentation include:
Function: Meaningful and sustained improvements from baseline in multiple functional endpoints were observed in both the 20 mg/kg (selected registrational dose) and 10 mg/kg1 DYNE-251 Q4W cohorts, through 12 and 18 months, respectively. Functional assessments included Stride Velocity 95th Centile (SV95C), North Star Ambulatory Assessment (NSAA), 10-Meter Walk/Run Time (10-MWR), and Time to Rise from Floor.
Starting at the 6-month timepoint, the SV95C change from baseline observed in both the 10 mg/kg and 20 mg/kg cohorts of DELIVER exceeded the published proposed minimal clinically important difference (MCID).
SV95C is a digital objective outcome measure of ambulatory performance in patients' normal daily environment and is accepted as a primary endpoint for DMD clinical trials in Europe.
Dystrophin expression: As previously reported, DYNE-251 demonstrated unprecedented near-full length dystrophin expression as measured by Western blot for patients with DMD who are amenable to exon 51 skipping. At the 6-month time point, patients treated with 20 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin expression of 8.72% of normal (adjusted for muscle content). Dyne has confirmed that the U.S. Food and Drug Administration precedent for using dystrophin as a surrogate biomarker for accelerated approval remains available.
Safety and tolerability: DYNE-251 has demonstrated a favorable safety profile based on 54 participants enrolled in the DELIVER trial. Since the prior update provided as of November 21, 2024, the safety profile remains unchanged, and no new treatment-related serious adverse events have been observed.2
970 doses of study drug have been administered to date over a period of 77.1 patient-years of follow-up with some patients followed for up to ~2.5 years.
546 doses of study drug at the 20 mg/kg dose level have been administered to date.3
Key Milestones for the DELIVER Trial
Dyne continues to pursue expedited approval pathways globally for DYNE-251 in patients with DMD who are amenable to exon 51 skipping.
Dyne has fully enrolled the Registrational Expansion Cohort of 32 patients as part of the DELIVER trial. Data from this cohort are planned for late 2025.
Dyne anticipates a potential Biologics License Application (BLA) submission for U.S. accelerated approval in early 2026.
Dyne Presentations at the 2025 MDA Clinical & Scientific ConferenceThe new assessment of the DELIVER trial is being presented in an oral presentation 'Safety and Efficacy from the Ongoing Phase 1/2 DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping' on Wednesday, March 19, at 8:30-8:45 a.m. CT by Kevin Flanigan, M.D., Director, Center for Gene Therapy, Abigail Wexner Research Institute of Nationwide Children's Hospital in Columbus, Ohio and Principal Investigator for the DELIVER Trial.
A poster with the same title will be available starting at 6:00 p.m. CT Sunday, March 16, 2025, through Tuesday, March 18, 2025, in the conference exhibit hall.
Both the oral presentation and poster are now available in the Scientific Publications & Presentations section of Dyne's website, along with several other posters and presentations including an encore presentation of the most recent positive results for DYNE-101 from the Phase 1/2 ACHIEVE trial in myotonic dystrophy type 1 (DM1).
About the DELIVER Trial
DELIVER is a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial evaluating the safety, tolerability and efficacy of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. The multiple ascending dose (MAD) portion of the study resulted in the selection of a registrational dose and regimen of 20 mg/kg every four weeks. A registrational expansion cohort to support potential regulatory submissions for expediated approvals, including accelerated approval in the U.S., is fully enrolled. The primary endpoint for this cohort is the change from baseline in dystrophin protein levels as measured by Western blot. For more information on the DELIVER trial, visit clinicaltrials.gov (NCT05524883) and euclinicaltrials.eu (2023-510351-31-00).
About DYNE-251
DYNE-251 is an investigational therapeutic being evaluated in the Phase 1/2 global DELIVER clinical trial for people living with DMD who are amenable to exon 51 skipping. DYNE-251 consists of a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1) which is highly expressed on muscle. It is designed to enable targeted muscle tissue delivery and promote exon skipping in the nucleus, allowing muscle cells to create internally shortened, near full-length dystrophin protein, with the goal of stopping or reversing disease progression. DYNE-251 has been granted fast track, orphan drug and rare pediatric disease designations by the U.S. Food and Drug Administration for the treatment of DMD mutations amenable to exon 51 skipping.
In addition to DYNE-251, Dyne is building a global DMD franchise and has preclinical programs targeting other exons, including 53, 45 and 44.
About Duchenne Muscular Dystrophy (DMD)
DMD is a rare disease caused by mutations in the gene that encodes for dystrophin, a protein critical for the normal function of muscle cells. These mutations, the majority of which are deletions, result in the lack of dystrophin protein and progressive loss of muscle function. DMD occurs primarily in males and affects an estimated 12,000 to 15,000 individuals in the U.S. and 25,000 in Europe. Loss of strength and function typically first appears in pre-school age boys and worsens as they age. As the disease progresses, the severity of damage to skeletal and cardiac muscle often results in patients experiencing total loss of ambulation by their early teenage years and includes worsening cardiac and respiratory symptoms and loss of upper body function by the later teens. There is no cure for DMD, and currently approved therapies provide limited benefit.
About Dyne Therapeutics
Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, the potential of DYNE-251, the anticipated timelines for reporting additional data from the DELIVER clinical trial, including the registrational cohort, the availability of accelerated approval pathways for DYNE-251 and expectations regarding the timing of submitting applications for U.S. accelerated approval, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'objective,' 'ongoing,' 'plan,' 'predict,' 'project,' 'potential,' 'should,' or 'would,' or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne's ability to enroll patients in clinical trials; whether results from preclinical studies and data from clinical trials will be predictive of the final results of the clinical trials or other trials; whether data from clinical trials will support submission for regulatory approvals; uncertainties as to the FDA's and other regulatory authorities' interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and as to the regulatory approval process for Dyne's product candidates; whether Dyne's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne's filings with the Securities and Exchange Commission (SEC), including the Company's most recent Form 10-K and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release.
During the OLE period, all participants in 10 mg/kg cohort were dose escalated to 20 mg/kg Q4W regimen.
DYNE-251 safety data as of February 7, 2025.
As of February 21, 2025.
Contacts:
InvestorsMia Tobiasir@dyne-tx.com781-317-0353MediaStacy Nartkersnartker@dyne-tx.com781-317-1938Sign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
2 hours ago
- Business Upturn
Brixton Metals Starts Drilling at the Catalyst Copper-Gold Porphyry Target with a Second Drill
VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the 'Company' or 'Brixton') is pleased to announce that it has begun drilling at the newly identified Catalyst Copper-Gold Porphyry Target at its wholly owned Thorn Project located in NW British Columbia, Canada. The Thorn Project is an underexplored copper-gold porphyry district with several large-scale exploration target areas identified. Drilling is ongoing at its Trapper Gold Target and a second drill is now operational at the Catalyst Target. Highlights A 2 km by up to 1 km copper-in-soil anomaly has been confirmed and refined, supported by soil geochemistry showing a classic calc-alkalic porphyry zonation: from a central Cu-Mo zone with depleted Zn, outward to Cu-Te-Se, and further to distal As-Sb anomalies. IP geophysical survey results reveal strong shallow conductivity and intense chargeability features at depth, closely aligning with expected porphyry-style alteration zones. Initial drilling will test depths to 500 meters, focusing on the copper-in-soil anomaly, gold-copper in surface rock samples, mapped surface phyllic and chlorite alteration zones, with chargeability signatures suggesting potential copper-gold porphyry mineralization. Chairman, CEO, Gary R. Thompson stated, ' The new Catalyst and Tempest Porphyry Targets have very quickly become exciting drill ready targets. The use of XRF analysis on soils has dramatically reduced the time to drill readiness. We are keen to see what kind of copper-gold grades Catalyst can generate from our initial drilling. In addition to the potential at the Catalyst Target both, the Trapper Gold Targets and the Camp Creek Gold Targets continue to shine brightly . To date in 2025, Brixton has drilled a total of 4,029m: 2,160m at Camp Creek over 12 holes and 1,869m at Trapper over 10 holes with most of these results pending. ' Figure 1. Thorn Targets and Copper Porphyry Targets within the Camp Creek Corridor. About the Catalyst Copper-Gold Target The Catalyst Porphyry Target is located approximately 6 km northeast from the Camp Creek Porphyry system, within a NE-SW corridor hosting several underexplored porphyry-style prospects. The Catalyst Target was significantly expanded to a 2 km x 1 km copper-in-soil anomaly, with real-time XRF analysis revealing a classic zonation pattern typical of porphyry systems, centered molybdenum with depleted zinc, transitioning outward through copper-tellurium-selenium, and flanked by distal arsenic-antimony anomalies. The soil geochemical anomaly was expanded by a combination of XRF and ICP-MS analysis. Geological mapping correlates the copper anomaly with outcropping feldspar porphyritic units, showing moderate phyllic alteration (quartz-sericite-pyrite) and moderate to strong chlorite-hematite-pyrite alteration. Phyllic alteration extends over 2 km, grading into propylitic assemblages (chlorite-epidote-pyrite-carbonates). Veining as stockworks and sheeted veins with sericite haloes within the central zone include quartz + pyrite ± chalcopyrite + chlorite + hematite ± bornite. Initial ICP-MS assays from surface rock chip-samples within the anomaly returned encouraging values of ~0.5% Cu and 1 g/t Au, for both styles of alteration phyllic and chlorite, consistent with potential porphyry mineralization. Figure 2. Updated Soil Geochemistry Map for the Catalyst Target. Recent induced polarization (IP) geophysics has outlined shallow conductive zones with extensive chargeability anomalies, coincident with both the surface geochemistry and mapped alteration. These features are interpreted as indicative of a phyllic halo and will be the focus of first-phase drill testing, targeting higher-grade copper mineralization at depth. Figure 3. IP Geophysical Profiles of the Catalyst Target Area. Figure 4. Surface Rock Samples from the Catalyst Target. Sample D201227 – phyllic altered feldspar porphyry with parallel quartz + chalcopyrite + pyrite veins. Sample B137968 – chlorite altered volcanoclastic rock with stockwork veins of chlorite + hematite + pyrite + chalcopyrite. Technical Note: Soil sample analysis at the Catalyst Target is being performed using in-house XRF facilities, enabling rapid, real-time geochemical screening to support field operations. Comparative analysis with laboratory-based ICP-MS assays has confirmed consistent results across key elements, including Cu, As, Sb, Te, Se, and W. Standard QA/QC protocols, such as blanks, duplicates, and certified reference standards, are routinely employed to ensure data integrity. Given the strong correlation between XRF and laboratory data, the company will continue to utilize this accelerated workflow throughout the exploration season to expedite evaluation of additional targets across the project area. Qualified Person (QP) Ms. Madeline Berry, is a Project Geologist for the Company who is a qualified person as defined by National Instrument 43-101. Ms. Berry has verified the referenced data and analytical results disclosed in this press release and has approved the technical information presented herein. About Brixton Metals Corporation Brixton Metals is a Canadian exploration company focused on the advancement of its mining projects. Brixton wholly owns four exploration projects: Brixton's flagship Thorn copper-gold-silver-molybdenum Project, the Hog Heaven copper-silver-gold Project in NW Montana, USA, which is optioned to Ivanhoe Electric Inc., the Langis-HudBay silver-cobalt-nickel Project in Ontario and the Atlin Goldfields Project located in northwest BC which is optioned to Eldorado Gold Corporation. Brixton Metals Corporation shares trade on the TSX-V under the ticker symbol BBB, and on the OTCQB under the ticker symbol BBBXF. For more information about Brixton, please visit our website at . On Behalf of the Board of Directors Mr. Gary R. Thompson, Chairman and CEO [email protected] For Investor Relations inquiries please contact: Mr. Michael Rapsch, Vice President Investor Relations. email: [email protected] or call Tel: 604-630-9707 Follow us on: LinkedIn | Twitter/X | Facebook | Instagram Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as 'anticipate', 'believe', 'plan', 'estimate', 'expect', and 'intend', statements that an action or event 'may', 'might', 'could', 'should', or 'will' be taken or occur, including statements that address potential quantity and/or grade of minerals, potential size and expansion of a mineralized zone, proposed timing of exploration and development plans, or other similar expressions. All statements, other than statements of historical fact included herein including, without limitation, statements regarding the use of proceeds. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: the need for additional financing; operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in the annual information form of the Company or other reports and filings with the TSXV and applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. Photos accompanying this announcement are available at: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash


Business Upturn
2 hours ago
- Business Upturn
Regenx Tech Provides Operational Update
EDMONTON, Alberta, July 24, 2025 (GLOBE NEWSWIRE) — Regenx Tech Corp. ('Regenx' or the 'Company') (CSE: RGX) (OTCQB: RGXTF) (FSE: YRS; WKN: A2DSW3) is pleased to provide an update on the commissioning of its newly upgraded facility in Newport, Tennessee. The Company has successfully completed water testing, a key phase in the restart process that confirms full system integration with the newly installed air purification system. This critical step was made possible following the receipt of final air permits. Advertisement 'We are thrilled to reach this stage,' said Rick Purdy, President of Regenx USA. 'The successful water test validates the extensive process enhancements we've implemented and marks a major step forward in our restart strategy. Our teams have worked tirelessly to get us here, and momentum continues to build.' Regenx is now conducting a full system test with chemistry, including equipment calibration and optimization. This represents the final protocol in the commissioning process and will pave the way for commercial production to resume. The Company will continue to provide updates on: Completion of commissioning Initiation of startup Ramp-up to full-scale production As Regenx advances toward its operational goals, the Company remains focused on delivering a clean, sustainable, and economically viable solution for recovering platinum and palladium from end-of-life diesel catalytic converters. For further information contact: REGENX TECH CORP. [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.


Business Wire
2 hours ago
- Business Wire
Geneoscopy's New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
ST. LOUIS--(BUSINESS WIRE)-- Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, received FDA approval to streamline the stool collection process for ColoSense®, its RNA-based colorectal cancer (CRC) screening test. The newly approved collection kit no longer requires patients to separate their sample into multiple containers. This improves ease of use and reduces barriers to at-home screening, 1 while maintaining clinical performance. 'We've taken a critical step toward improving the at-home colorectal cancer screening experience by removing one of the most burdensome aspects for patients—the scraping of stool,' said Dr. Erica Barnell, Chief Medical & Science Officer of Geneoscopy. 'The new collection kit simplifies the process for collecting a patient's stool sample. By eliminating the most confusing and undesirable step, we believe ColoSense will drive higher adherence and better outcomes.' ColoSense is indicated for individuals aged 45 and older who are at average risk for CRC. It uses advanced RNA technology to detect biomarkers associated with CRC and advanced adenomas (AA)—precancerous growths that can develop into cancer if left untreated. As the only FDA-approved RNA-based test for CRC screening, ColoSense demonstrated 93% sensitivity for CRC and 45% sensitivity for AA in average-risk individuals. Among average-risk individuals aged 45 to 49, where CRC incidence is on the rise, the test demonstrated 100% sensitivity for CRC and 44% sensitivity for AA.* Despite the availability of multiple screening options, an estimated 44 million people aged 45-75 remain unscreened for CRC. 2 To help address a common barrier to stool-based screening, the updated ColoSense collection kit removes the need to scrape the sample. This improvement is expected to increase patient compliance, lower the rate of collection errors, and reduce the frequency of invalid samples. This ease of use can translate into fewer missed screenings and a greater overall impact on population health. 'To exceed 80% compliance for colorectal cancer screening, the patient experience for stool-based screening must be improved,' said Andrew Barnell, Chief Executive Officer of Geneoscopy. 'The new ColoSense test does that, offering patients everything they like about at-home, high-sensitivity screening, but now, with an easier collection process.' ColoSense is included in National Comprehensive Cancer Network (NCCN) guidelines, based on an evaluation of the strength of its clinical evidence and the robust science behind the technology. The test will be available through Geneoscopy's strategic collaboration with Labcorp, expanding access for providers and patients across the United States. ColoSense represents a significant advancement in noninvasive stool testing options, reinforcing the importance of accessible tools that help reach individuals who are less likely to undergo colonoscopy. About ColoSense ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults aged 45 years or older who are at the typical average risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. Results from Geneoscopy's pivotal CRC-PREVENT trial were published in The Journal of the American Medical Association (JAMA). For more information, visit About Geneoscopy, Inc. Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit and follow the company on LinkedIn. References Luque JS, Wallace K, Blankenship BF, et al. Formative Research on Knowledge and Preferences for Stool-based Tests compared to Colonoscopy: What Patients and Providers Think. J Community Health. 2018;43(6):1085-1092. doi:10.1007/s10900-018-0525-x Hyams T, Mueller N, Curbow B, et al. Screening for colorectal cancer in people ages 45–49: research gaps, challenges and future directions for research and practice, Transl. Behav. Med, Volume 12, Issue 2, Feb 2022, Pages 198–202. *ColoSense identified 5/5 colorectal cancers and 37/84 advanced adenomas.